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Accumulating evidence indicates that CDK2 promotes hyperproliferation and is associated to poor prognosis in
multiple cancer cells. However, the physiological role of CDK2 in GBM and the biological mechanism still remains
unclear. In this study, we identified that CDK2 expression was significantly enriched in GBM tumors compared
with normal brain. Additionally, CDK2 was functionally required for tumor proliferation and its expression was
associated to poor prognosis in GBM patients. Mechanically, CDK2 induced radio resistance in GBM cells and
CDK2 knock down increased cell apoptosis when combined with radiotherapy. Therapeutically, we found that
CDK2 inhibitor attenuated tumor growth both in vitro and in vivo. Collectively, CDK2 promotes proliferation,
induces radio resistance in GBM, and could become a therapeutic target for GBM.
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Glioblastoma (GBM) is one of the most common malignant primary
brain tumors in human adults with the median survival in the range of
14 to 18 months despite multimodality treatment comprising
maximal safe resection, radiotherapy, and concomitant and adjuvant
chemotherapy [1,2]. During their clinical course, almost all patients
suffer a post-treatment recurrence then become resistant to both
radiotherapy and chemotherapy. Therefore, the drug resistance, high
recurrence and poor prognosis of GBM promote us to identify novel
biomarkers and explore novel therapeutic targets for the available
clinical treatment of GBM.
Cyclin-dependent kinases (CDKs) are heterodimeric complexes
composed of a catalytic kinase subunit and a regulatory cyclin
subunit, and comprise a family divided into two groups based on their
roles in cell cycle progression and transcriptional regulation [3,4].
There are totally 13 CDKs in human cells and five of them, named
CDK1, CDK2, CDK3, CDK4, and CDK6, respectively, are
involved in the regulation of cell cycle [5]. Cyclin-dependent kinases
2 (CDK2) is one of the most essential regulators for the transition and
progression in a cell-division cycle and plays a crucial role in
regulating multiple events of cell division cycle including centrosome
duplication, DNA synthesis, G1-S transition, and modulation of G2
progression [6–9]. Accumulating evidence has been shown that
CDK2 is functionally associated with hyperproliferation in multiple
cancer cells and could be regarded as a potentially therapeutic targetfor cancer therapy [6]. Recent study indicated that CDK2 expression
level was elevated in human cholangiocarcinoma tissues and
apoptosis-related protein-1 dependent suppression of CDK2 induced
cell cycle arrest then restrain tumor growth in cholangiocarcinoma
[10]. Another study showed that inhibition of CDK2 kinase activity
reduced tumor proliferation via selectively targets the CD44+/
CD24−/Low stem-like cells in triple-negative breast cancer when
combined with conventional chemotherapy [11]. Additionally, a
newly published study demonstrated that CDK2 inhibitor exhibits
anti-cancer effect in human hepatoma HepG2 and Huh7 cells and
significantly inhibited tumor growth [12]. Lim et al. identified CDK2
as a direct therapeutic target of curcumin in colon cancer cells via cell
cycle arrest in HCT116 cells [13]. Taken together, CDK2-dependent
cell cycle regulation plays an essential role in tumor growth and might
be a potential therapeutic target for cancer treatment. However,
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biological mechanism in GBM still remains unclear.
In this study, we identified that CDK2 expression was significantly
enriched in GBM tumors and was functionally required for tumor
proliferation both in vitro and in vivo. Furthermore, high CDK2
expression was associated to poor prognosis in GBM patients.
Mechanically, CDK2 induced radio resistance in GBM cells and
CDK2 knock down increased apoptosis in GBM cells when
combined with radiotherapy. Therapeutically, we found that
CDK2 inhibitor attenuated tumor growth both in vitro and in vivo.
Collectively, CDK2 promotes proliferation, induces radio resistance
in GBM, and could be a therapeutic target for GBM.
Materials and Methods
Ethics
All the usage of experimental animals (nude mice) in this study is
approved by the Scientific Ethics Committee of School of Medicine,
Xi'an Jiaotong University, Xi'an, China (No. 2016-085). The
collection and usage of the human tumor samples and patient
information are approved by the Scientific Ethics Committee of First
Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (No.
2016-18).
Reagents and Antibodies
The following reagents and primary antibodies are used in this
study: DMEM-F12 (Gibco, 10,565-018), Fetal bovine serum
(Gibco, 10,082-147), Accutase solution (Sigma, A6964-100), Alamar
Blue (Invitrogen, DAL1100), RIPA buffer (Sigma, R0278),
Phosphatase inhibitor cocktail (Sigma, P0044), Protease inhibitor
cocktail (P8340), Bradford (BIORAD, 500-0006), BSA used in
Bradford assay (BioLabs, B9001S), PageRuler plus prestained protein
(Thermo scientific, 26,619), iScript Reverse Transcription supermix
for qRT-PCR (Bio-rad, 170-8841), shCDK2 lentivirus particles
(Origene, TL320291V), CDK2 Inhibitor II (Santa Cruz Biotech-
nology, CAS 222035-13-4), Alexa Fluor® 488 Annexin V/Dead Cell
Apoptosis Kit (Thermo Fisher Scientific,V13241). Anti-CDK2
(Abcam, ab54513, Mouse, used for WB), anti-CDK2 (Abcam,
ab32147, Rabbit, used for IHC), β-actin (Sigma, A5316, Mouse,
used for WB).
In Vitro Cell Cultures
Glioblastoma cells are cultured in DMEM/F12 medium contain-
ing 10% FBS supplement (vol%). The culture medium is replaced
every 5 to 10 days. Normal Human Astrocytes (NHA, Lonza) are
used as a control sample in this study.
RNA Isolation and Quantitative Real-Time PCR
RNA is isolated by using RNeasy mini kit (QIAGEN) according to
the manufacturer's instructions. RNA concentration is determined
using a Nanodrop 2000 (Thermo scientific). cDNA is synthesized by
using iScript reverse transcription supermix for qRT-PCR (Bio-rad)
according to the manufacturer's protocol. The reverse-transcribed
cDNA is analyzed by quantitative RT-PCR (qRT-PCR), and
GAPDH or 18 s is used as an internal control. Each qRT-PCR
includes a 10 μl reaction mixture per well that includes 2.5 μl cDNA,
0.5 μl forward primer (0.5 μM), 0.5 μl reverse primer (0.5 μM),
1.5 μl of DNase/RNase-free distilled water, and 5 μl SYBR green
reagent (QIAGEN). The following cycles are performed during DNA
amplification: 94 °C for 2 min, 40 cycles of 94 °C (30 s), 60 °C (30 s),and 72 °C (40 s).18S is used as an internal control. The primer sequences
are showed below: CDK2-Forward: GAATCTCCAGGGAATAGGGC,
CDK2-Reverse: CTGAAATCCTCCTGGGCTG, 18S-Forward:
GGCCCTGTAATTGGAATGAGTC and 18S-Reverse: CCAAGAT
CCAACTACGAGCTT.
Western Blotting
The cell lysates are prepared in RIPA buffer containing 1%
protease and 1% phosphatase inhibitor cocktail (Sigma Aldrich) on
ice. The sample protein concentrations are determined by the
Bradford method. Equal amounts of protein lysates (10 μg/lane) are
fractionated on NuPAGE Novex 4% to 12% Bis-Tris Protein gel
(Invitrogen) and transferred to a PVDF membrane (Invitrogen).
Subsequently, the membranes are blocked with 5% skimmed milk for
1 h and then treated with the relevant antibody at 4 °C overnight.
Protein expression is visualized with Amersham ECL Western Blot
System (GE Healthcare Life Sciences). β-Actin serves as a loading
control.
Flow Cytometry Analysis
Harvest the cells after the incubation period and wash in cold
phosphate-buffered saline for 3 times (PBS). Re-centrifuge the
washed cells (from step 2), discard the supernatant and suspend
5 × 105 cells in 100 μl 1X Annexin-binding buffer. Add 5 μl Alexa
Fluor® 488 annexin V and 1 μl 100 μg/ml PI working solution
thatwas prepared according to the protocol. Incubate the cells at room
temperature for 15 minutes then add 400 μl 1× annexin -binding
buffer, mix gently and keep the samples on ice. Analyze the stained
cells by measuring the fluorescence emission at 530 nm and 575 nm
with 488 nm excitation.
Immunohistochemistry Staining
For IHC, experimental mice are sacrificed and perfused with
ice-cold PBS followed by 4% (wt/ vol) paraformaldehyde (PFA).
Then brains are harvested and fixed in 4% (wt/vol) PFA for 24 h and
then transferred into 10% formalin. Brain sections are incubated with
the indicated primary antibodies overnight at 4 °C, followed by
incubation with an HRP-conjugated secondary antibody for 1 h at
room temperature. Signals are detected using DAB substrate kit
(Vector). Nuclei are counter stained with hematoxylin or Hoechst,
respectively. Samples incubate without primary antibodies are used as
negative controls.
German Immunohistochemical Score
Percentage of positive cells is classified as 0 (negative), 1 (up to 10%),
2 (11% to 50%), 3 (51% to 80%), or 4 (N80% positive cells),
staining intensity is classified as 0 (no staining), 1 (weak), 2
(moderate), or 3 (strong). The final immunoreactivity score is defined
as the multiplication of both grading results (percentage of positive
cells × staining intensity).
In Vivo Intracranial Xenograft Tumor Models
Six-week-old nude mice are used for GBM intracranial implan-
tation. All animal experiments are carried out in Xi'an Jiaotong
University. The GBM suspension (1 × 105 cells in 5 μl of PBS)
transduced with non-target or shCDK2 lentivirus is injected into the
brains of nude mice after anesthesia. At least six mice are used for each
group. Drug treatment is done through tail vein injection and starts
from 5 days after tumor cells are implanted. Mice were monitored
once a day for symptoms related to tumor growth including an arched
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euthanized by overdose of anesthesia of ketamine and xylazine after a
total body weight loss of 40% or severe symptoms were observed.
Statistical Analysis
All the data are presented as mean ± SD. The number of replicates
for each experiment is stated in the figure legend. Statistical
differences between two groups are evaluated by two-tailed t-test.
The comparison among multiple groups are performed by one-way
analysis of variance (ANOVA) followed by Dunnett's posttest. The
statistical significance of Kaplan–Meier survival plot is determined byFigure 1. CDK2 expression was enriched in GBM. (a) Genome-wide tr
CDK2 is one of the most up-regulated kinases in GBM samples comp
CDK2 expression was elevated in GBM samples. (c) Analysis of TCG
subgroups of GBM (classical, mesenchymal, neural and proneural) co
demonstrated that CDK2 expression in GBM is significantly higher tha
showed CDK2mRNA expression was elevated in 3 GBM cell lines (U1
blotting analysis indicated that CDK2 protein expression was enrichelog-rank analysis. Statistical analysis is performed by Prism 6
(Graphpad prism), unless mentioned otherwise in figure legend.
P b .05 is considered as statistically significant.
Results
CDK2 Expression was Enriched in GBM
In this study, we first sought to characterize the role of CDK2 in
GBM tumors. To this end, we analyzed the microarray data from
TCGA database and find that CDK2 is the most up-regulated
kinase-encoding gene in GBM samples compared to normal tissueanscriptome microarray analysis from TCGA database showed that
ared to normal tissue. (b) Analysis of Sun.'s database indicated that
A database indicated that CDK2 was highly expressed in all the 4
mpared with non tumor tissue. (d) Analysis of Rembrandt database
n non tumor and other types of glioma groups. (e) qRT-PCR analysis
38, U251, U87) compared with normal astrocytes (NHA). (f) Western
d in 3 GBM cell lines compared with normal astrocytes.
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database (GSE 4290) database indicated that CDK2 was highly
expressed in GBM when compared with normal brain and low-grade
glioma [14] (Figure 1b). Additionally, we found that CDK2
expression was significantly enriched in all the four subgroups of
GBM (classical, mesenchymal, neural, and proneural) compared with
non-tumor tissue (Figure 1c). The data from Rembrandt database also
demonstrated that CDK2 mRNA expression in GBM is significantly
higher than non-tumor and other types of glioma groups (Figure 1d).
To confirm this, qRT-PCR using 3 GBM cell lines and normal
human astrocyte (NHA) was performed and the result exhibited the
higher expression of CDK2 protein in GBM (Figure 1e). The
sequences of these primers are described in methods and materials.
Similar to the mRNA expression, Western blotting data demonstrat-Figure 2. CDK2 was functionally required for GBM proliferation both in
shRNA against CDK2 (shCDK2) or non-targeting control (shNT). (b) W
CDK2 (shCDK2) or non-targeting control (shNT). (c) In vitro cell grow
proliferation of U87 cells (P b .01, n = 6, with one-way ANOVA). (d) R
intracranial transplantation of U87 cells transduced with shRNA again
analysis of nudemice harboring intracranial tumor derived from U87 c
log-rank test).ed the same result (Figure 1f). Taken together, these data indicated
that CDK2 was preferentially expressed in GBM.
CDK2 was Functionally Required for GBM Proliferation Both
In Vitro and In Vivo
To examine the pathophysiological role of CDK2 in GBM, an
in vitro GBM cell line (U87) was transduced with either lentiviral
shRNA clone for CDK2 (shCDK2) or a non-targeting shRNA
(shNT; negative control). qRT-PCR was performed to confirm the
knockdown efficiency of the lentivirus (Figure 2a). Additionally,
Western blotting exhibited that CDK2 protein expression was
markedly decreased by shCDK2 (Figure 2b). In vitro cell growth
kinetics of shCDEK2 transfected U87 cells was diminished
proportionally to the reduction levels of CDK2 (Figure 2c). Next,vitro and in vivo. (a) qRT-PCR analysis of U87 cells transduced with
estern blot analysis of U87 cells transduced with shRNA against
th assay showing shRNA against CDK2 (shCDK2) inhibited cell
epresentative images of H&E stained mouse brain section after the
st CDK2 (shCDK2) or non-targeting control (shNT). (e) Kaplan–Meier
ells transduced with shNT (n = 5), shCDK2 (n = 5) (P = .0066, with
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formation. To this end, we used U87 cells-derived mouse intracranial
tumor models. The results showed that mice xenografted with shNT
transfected U87 rapidly formed lethal hyper vascular GBM-like
tumors within 30 days (median survival being 24.7 ± 2.94 days),
while a longer survival could be observed in mice xenografted
shCDK2 transfected U87 cells (median survival being 35.6 ± 6.23
days), highlighting a potent anti-tumorigenesis effects of CDK2
knock-down (Figure 2, d and e). All together, these findings indicated
that CDK2 is required for GBM proliferation both in vitro and
in vivo.Figure 3. Enhanced CDK2 expression was highly expressed in GBM a
displayed a strong expression at protein level in the Human protein A
CDK2. (c) Analysis of CDK2 in glioma samples and non-tumor brain s
samples compared to low grade glioma samples. (d) Kaplan–Meier a
survival of 41 glioma patients (CDK2high samples versus CDK2low sam
data indicated the inverted correlation between CDK2 mRNA expresEnhanced CDK2 Expression was Highly Expressed in GBM
and was Associated to Poor Prognosis in GBM Patients
Given these experimental data, we sought to ask whether CDK2
could be a clinical target in GBM. To this end, we first checked the
Human Protein Atlas (THPA) and found that CDK2 expression was
enriched in compared to low grade glioma (Figure 3a). We then
examined CDK2 expression in 41 glioma patient samples of varying
grades, which were collected from 2006 to 2015 in First Affiliated
Hospital of Xi'an Jiaotong University, by immunohistochemical and
Germany immunohistochemical scores (GIS) was used to quantify
the expression levels. As a result, we found CDK2 was highlynd was associated with poor prognosis in GBM patients. (a) CDK2
tlas dataset. (b) Representative immunohistochemically image of
amples showed CDK2 is highly expressed in high grade glioma
nalysis evaluating the correlation between CDK2 expression and
ples, P = .0262, with log-rank test). (e) Analysis of the Rembrandt
sion and post-surgical survival of GBM patients.
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glioma samples (6 out of 23) (Figure 3b and c). Furthermore, we
found that the overall survival period is significantly longer in theFigure 4. CDK2 regulated radio resistance in GBM. (a) Genome-wide tr
most up-regulated kinases in GBM cells post-irradiation (12Gy) com
expression in U87 cells post-irradiation (12Gy) compared to naïve U8
expression in U87 cells post-irradiation (12Gy) compared to naïve U8
infected with shNT and shCDK2 then treated with or without radiatio
using U87 cells infected with shNT and shCDK2 then treated with or w
vitro cell growth assay for U87 cells transduced with shNT or shCDK
analysis for apoptosis with Annexin V antibody and Propidium Iodide
radiation treatment (12 Gy).CDK2 low expressed group (with a median survival 28 months) than
CDK2 high expressed group (with a median survival 9 months)
(Figure 3d). Then we checked the data from Rembrandt database alsoanscriptomemicroarray analysis showed that CDK2 was one of the
pared to naïve GBM cells. (b) qRT-PCR analysis for CDK2 mRNA
7 cells (P b .01, with t-test). (c) Western analysis for CDK2 protein
7 cells. (d) qRT-PCR analysis for CDK2 expression using U87 cells
n treatment (12 Gy). (e) Western blot analysis for CDK2 expression
ithout radiation treatment (12 Gy). β-actin served as a control. (f) In
2 with or without radiation treatment (12 Gy). (g) Flow cytometry
using U87 cells transduced with shNT or shCDK2 with or without
554 Cyclin-dependent kinase 2 and glioblastoma Wang et al. Translational Oncology Vol. 9, No. 6, 2016demonstrated that GBM patients with higher CDK2 expression
exhibited significantly shorter survival periods compared to those with
intermediate or low expression group (Figure3e). Collectively, these
data indicated that CDK2 might be a clinically relevant molecular
target in GBM.
CDK2 Regulated Radio Resistance in GBM
To identify the mechanism of CDK2 regulated GBM tumorigen-
esis and proliferation, we then assumed that CDK2 might contribute
to radio-resistance in GBM, thereby leading to tumor recurrence after
therapeutic failure. The DNA microarray analysis focusing on 668
kinase-encoding genes with 2 GBM cell lines demonstrated that
CDK2 was the top 2 gene which were up-regulated after irradiation at
12 Gy (Figure 4a). To confirm this, we treaded U87 cells with or
without radiotherapy for 12 Gy and purified mRNA or protein 72 h
after treatment. qRT-PCR analysis indicated that CDK2 expression
level was significantly elevated at both mRNA level (Figure 4b) and
protein level after radio treatment (Figure 4c). To investigate whether
CDK2 is necessary for GBM cells to maintain radio resistance, we
then combined CDK2 knock down together with radiotherapy.
qRT-PCR and western blotting results showed the post-radiation
elevation of CDK2 was reduced by shCDK2 (Figure 4, d and e).
In vitro cell proliferation was dramatically decreased by shCDK2
when combined with radio treatment (Figure 4f). At the same time,
we performed flow cytometry for apoptosis with Annexin V (AV)
antibody and Propidium Iodide (PI) by using shCDK2 transduced
U87 cells with or without radiation treatment (12 Gy). The results
indicated that proportions of cells undergoing early (AV+; PI−) and
late (AV+; PI+) apoptosis were both dramatically increased after
radiation, when combined with CDK2 knockdown in comparison to
radiation alone (Figure 4g). Taken together, CDK2-dependent radio
resistance was essential for GBM tumorigenesis and recurrence after
therapeutic treatment.
CDK2 Inhibitor Attenuated Tumor Growth by Increasing
Radio Sensitivity in GBM
For the purpose of CDK2 targeting therapeutic development, we
sought to identify whether selectively CDK2 inhibition could eliminate
tumorigenesis and radio resistance. To this end, an ATP-competitive
CDK2 inhibitor, CDK2 inhibitor II, was used for in vitro and in vivo
experiments (Figure 5a). To characterize the efficacy of thisCDK2
inhibitor, we started from investigating the IC50s of CDK2 inhibitor II
in different GBM cell lines. As expected, in vitro sensitivities of these
GBM cells were correlated with their CDK2 expression levels and
normal astrocytes showed more resistance to CDK2 inhibitor II
(Figure 5, b and c). Furthermore, in vitro cell proliferation was
significantly eliminated by CDK2 inhibitor II when combined with
radiation compared with radiotherapy alone (Figure 5d). Flow
cytometry results indicated that radiation treatment significantly
increased the proportion of apoptotic cells when combined with C3a
together (Figure 5e). To investigate the effect of CDK2 inhibitor II on
in vivo tumor initiation and propagation, mouse intracranial tumor
models were used and CDK2 inhibitor II treatment started from 5 days
after implanted U87 cells then continued for 7 days through tail vein
injection for 20 mg/kg/day. A decreased tumor growth and longer
survival could be observed after CDK2 inhibitor II treatment in mice
(Figure 5, f and g), indicating that CDK2 inhibition was capable of
abolishing GBM growth both in vitro and in vivo and might be a
promising therapeutic target for GBM therapy.Discussion
Accumulating data suggests that CDKs are targets of interest for
anticancer drug development as uncontrolled activation of CDKs can
accelerate tumor proliferation [15]. Among all the CDKs, CDK2 was
identified as a key kinase in tumorigenesis and proliferation in a range
of cancer types including lung cancer, liver cancer, colon cancer and
breast cancer [11–13]. In this study, we identified CDK2 expression
was significantly elevated in glioma tumor especially in GBM and was
functionally required for GBM cell proliferation and tumorigenesis.
However, the molecular mechanism in this progress still remains
unclear. Recent study identifies p53-dependent repression of CDK2
as a key mechanism during cellular senescence, essential for cell cycle
exit [16,17]. It also suggests that, clinically, CDK2 inhibition may be
effective in driving pre-tumorigenic cells into a senescent state,
thereby abrogating tumor progression by preventing further
proliferation and possible accumulation of genetic aberrations that
may otherwise lead to bypass of senescence [16,17]. Another study
demonstrates that CDK2 promotes invasion in GBM by phosphor-
ylating Rb1, up-regulating CDC2, inactivating caldesmon and
increasing MLC phosphorylation and decreases in KAP levels have
the ability to activate this pathway by increasing CDK2 activation
[18]. Nonetheless, whether CDK2 functions in GBM tumor growth
depends on cell cycle regulation or there is still some other mechanism
existing in this process still remains unclear and further studies are
needed to investigate this.
Radio resistance has been proven to be the key factor of poor
clinical prognosis and tumor recurrence in GBM patients. Herein, we
found that CDK2 was one of the most up-regulated kinase encoding
genes in GBM after radio treatment and CDK2-dependent radio
resistance was essential for GBM tumorigenesis and recurrence after
therapeutic treatment. However, the detailed mechanism and
down-stream pathway of CDK2 in GBM are poorly identified. It
has been shown that a small subpopulation of tumor cells among the
whole tumor, termed glioma stem cells (GSCs), is likely responsible
for tumorigenesis, treatment resistance, and recurrence [19–22].
Opyrchal et al. reported that aberrant activation of cyclin E/ CDK2
oncogenic signaling is essential for the maintenance and expansion of
CD44+/CD24−/Low cancer stem-like cell subpopulation in inflam-
matory breast cancer (IBC) and CDK2 kinase activity may represent a
novel targeted therapeutic approach to treat aggressive IBC tumors
[11]. Additionally, another research indicates that phosphorylation of
EZH2 at T416 by CDK2 contributes to the malignancy of triple
negative breast cancer [23,24]. EZH2 is well known as one of the core
functional components in polycomb repressive complexes 2 (PRC2),
which functions as a lysine methyltransferase and catalyzes
tri-methylation of histone H3 and EZH2 phosphorylation has been
proved to be indispensable for tumorigenesis and therapy resistance in
GBM [25–27]. Combined with our findings, it raises the possibility
that CDK2-mediated EZH2 phosphorylation is important for GSC
stemness maintainance and thus induces therapy resistance in GBM
and further studies need to be done to confirm this hypothesis.
All together, our findings identified CDK2 is significantly elevated
in GBM tumors and is functionally required for tumor proliferation
both in vitro and in vivo. Furthermore, high CDK2 expression is
associated to poor prognosis in GBM patients. Mechanically, CDK2
induces radio resistance in GBM cells and CDK2 knock down
increases apoptosis in GBM cells when combined with radiotherapy.
Therapeutically, we find that CDK2 inhibitor attenuates tumor
growth and reduces radio resistance in GBM. In conclusion, CDK2
Figure 5. CDK2 inhibitor attenuated tumor growth by increasing radio sensitivity in GBM. (a) Chemical structure of CDK2 Inhibitor II. (b) In
vitro cell viability assay for CDK2 Inhibitor II with 3 GBM cell lines (U138, U251, U87) compared with normal astrocytes (NHA). (c) IC50s of
CDK2 Inhibitor II in 3 GBM cell lines (U138, U251, U87) compared with normal astrocytes (NHA). (d) In vitro cell growth assay showed that
CDK2 Inhibitor II decreased cell proliferation of U87 when combined with radiation (P b .001, with ELDA analysis). (e) Flow cytometry
analysis for apoptosis with Annexin V antibody and Propidium Iodide using U87 cells pretreated with CDK2 Inhibitor II with or without
radiation treatment (12 Gy). (f) Representative images of H&E stained mouse brain section after the intracranial transplantation of U87
cells then followed continuously 7-day CDK2 Inhibitor II treatment or placebo by tail vein injection. (g) Kaplan–Meier analysis was
performed for the comparison of survival in U87 implanted mice treat with or without CDK2 Inhibitor II (P = .0066, with log-rank test).
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be a therapeutic target for GBM.
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